<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05085912</url>
  </required_header>
  <id_info>
    <org_study_id>DAAF</org_study_id>
    <nct_id>NCT05085912</nct_id>
  </id_info>
  <brief_title>Driver Ablation of Persistent Atrial Fibrillation With Severe Atrial Fibrosis.</brief_title>
  <official_title>A Randomized Control Study of Driver Ablation of Persistent Atrial Fibrillation With Severe Atrial Fibrosis: a Chinese Registry Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Chest Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Chest Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, randomized parallel control clinical trial, to demonstrate the role of&#xD;
      driver mechanism in maintenance substrate of persistent atrial fibrillation with severe&#xD;
      atrial fibrosis, and evaluate the clinical outcomes of driver mapping and ablation strategy&#xD;
      in patients with persistent atrial fibrillation with severe atrial fibrosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label, randomized parallel control clinical trial. Patients with persistent&#xD;
      atrial fibrillation with severe atrial fibrosis are 1:1:1 randomized into group A&#xD;
      (circumferential pulmonary vein isolation + linear ablation + bi-atrial mapping + driver&#xD;
      ablation), group B (circumferential pulmonary vein isolation + linear ablation + posterior&#xD;
      wall box isolation) and group C (circumferential pulmonary vein isolation + linear ablation +&#xD;
      vein of Marshall ethanol infusion). Postoperative recurrence rate and other indicators are&#xD;
      analyzed to demonstrate the role of driver mechanism in maintenance substrate of persistent&#xD;
      atrial fibrillation with severe atrial fibrosis and evaluate the clinical outcomes of driver&#xD;
      mapping and ablation strategy in patients with persistent atrial fibrillation with severe&#xD;
      atrial fibrosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative atrial fibrillation (AF)/atrial flutter (AFL)/atrial tachycardia (AT) recurrence rate</measure>
    <time_frame>up to 12 months after ablation</time_frame>
    <description>AF/AFL/AT recurrence is defined as presence of documented AF/AFL/AT episodes of 30 seconds or longer duration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intraoperative AF termination rate</measure>
    <time_frame>through ablation completion, an average of 3 hours</time_frame>
    <description>AF termination is defined as conversion to sinus rhythm or stable AFL/AT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative AF recurrence rate</measure>
    <time_frame>up to 12 months after ablation</time_frame>
    <description>AF recurrence is defined as presence of documented AF episodes of 30 seconds or longer duration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative AFL/AT rate</measure>
    <time_frame>up to 12 months after ablation</time_frame>
    <description>occurrence of AFL/AT is defined as presence of documented AFL/AT episodes of 30 seconds or longer duration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of complications</measure>
    <time_frame>up to 12 months after ablation</time_frame>
    <description>death, atrioesophageal fistula, cardiac tamponade/perforation, myocardial infarction, stroke/cerebrovascular accident, thromboembolism, diaphragmatic paralysis, pneumothorax, heart block, pulmonary vein stenosis, pulmonary edema, pericarditis and major vascular access complication or bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the diameter of the left atrium</measure>
    <time_frame>up to 12 months after ablation</time_frame>
    <description>Changes in the diameter of the left atrium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the left ventricular ejection fraction</measure>
    <time_frame>up to 12 months after ablation</time_frame>
    <description>Changes in the left ventricular ejection fraction</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Persistent Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Circumferential pulmonary vein isolation + linear ablation + bi-atrial mapping + driver ablation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Circumferential pulmonary vein isolation + linear ablation + posterior wall box isolation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Circumferential pulmonary vein isolation + linear ablation + vein of Marshall ethanol infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Circumferential pulmonary vein isolation + linear ablation + bi-atrial mapping + driver ablation</intervention_name>
    <description>Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with bi-atrial mapping and driver ablation.</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Circumferential pulmonary vein isolation + linear ablation + posterior wall box isolation</intervention_name>
    <description>Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with posterior wall box isolation.</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Circumferential pulmonary vein isolation + linear ablation + vein of Marshall ethanol infusion</intervention_name>
    <description>Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with vein of Marshall ethanol infusion.</description>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged 18 to 80 years old;&#xD;
&#xD;
          2. Persistent AF with severe atrial fibrosis;&#xD;
&#xD;
          3. Nonresponse or intolerance to â‰¥1 antiarrhythmic drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. With uncontrolled congestive heart failure;&#xD;
&#xD;
          2. Having significant valvular disease;&#xD;
&#xD;
          3. With myocardial infarction or stroke within 6 months of screening;&#xD;
&#xD;
          4. With Significant congenital heart disease;&#xD;
&#xD;
          5. Ejection fraction was &lt;40% measured by echocardiography;&#xD;
&#xD;
          6. Allergic to contrast media;&#xD;
&#xD;
          7. Contraindication to anticoagulation medications;&#xD;
&#xD;
          8. Severe pulmonary disease e.g. restrictive pulmonary disease, chronic obstructive&#xD;
             disease (COPD);&#xD;
&#xD;
          9. Left atrial (LA) thrombus;&#xD;
&#xD;
         10. Having any contraindication to right or left sided heart catheterization; 11. Previous&#xD;
             atrial fibrillation ablation;&#xD;
&#xD;
        12. Presence of an implanted cardioverter-defibrillator; 13. Previous history of cardiac&#xD;
        surgery; 14. Poor general health; 15. Life expectancy less than 6 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mu Qin, M.D.</last_name>
    <phone>+8613052320103</phone>
    <email>qinmuae@163.com</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 5, 2021</study_first_submitted>
  <study_first_submitted_qc>October 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2021</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Chest Hospital</investigator_affiliation>
    <investigator_full_name>Xu Liu</investigator_full_name>
    <investigator_title>Professor, deputy director of cardiology department of Shanghai Chest Hospita</investigator_title>
  </responsible_party>
  <keyword>persistent atrial fibrillation</keyword>
  <keyword>severe atrial fibrosis</keyword>
  <keyword>driver ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

